The process of changing national malaria treatment policy: Lessons from country-level studies

Health Policy and Planning

Volumn 19, Issue 6, 2004, Pages 356-370

  Williams, Holly Ann ^a,d,e,g   Durrheim, David ^b,f   Shretta, Rima ^c,f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JAMES COOK UNIVERSITY   (Australia)

^c MANAGEMENT SCIENCES FOR HEALTH   (United States)

^d Public Health Service   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g World Hlth Org Lymph F C C ^*  (United States)

Author keywords

Drug policy; Malaria; Policy development; Treatment guidelines; Treatment policy

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE;

DECISION MAKING; DRUG RESISTANCE; ENDEMIC DISEASE; HEALTH CARE POLICY; KENYA; MALARIA; MALAWI; MANAGEMENT; PERU; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; RESOURCE ALLOCATION; REVIEW; SOUTH AFRICA; TANZANIA;

AFRICA; ANTIMALARIALS; DECISION MAKING; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; MALARIA, FALCIPARUM; PERU; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 8144224198     PISSN: 02681080     EISSN: None     Source Type: Journal    
DOI: 10.1093/heapol/czh051     Document Type: Review

References (73)

1. Abdulla S, Goodman C, Coleman P et al. 2000. The costs, effects and cost-effectiveness of changing the first line drug for the treatment of malaria in Tanzania. London and Liverpool: The Malaria Consortium, London School of Hygiene and Tropical Medicine/Liverpool School of Tropical Medicine.
2. ACTMalaria. 2000. Course curriculum. Drug policy development. (Trial Editions I and II). Bangkok: ACTMalaria.
3. Agyepong I, Manderson L. 1994. The diagnosis and management of fever at household level in the Greater Accra Region, Ghana. Acta Tropica 58: 317-30.
4. Asenso-Okyere WK. 1994. Socioeconomic factors in malaria control. World Health Forum 15: 265-8.
5. Asenso-Okyere WK, Dzator JA. 1997. Household cost of seeking malaria care. A retrospective study of two districts in Ghana. Social Science and Medicine 45: 659-67.
6. Atun R, Lennox-Chugani N, Drobniewski F, Samyshkin Y, Coker RJ (in press). Capturing health systems complexity: a conceptual framework for development, implementation, evaluation, and monitoring of communicable disease programmes. European Journal of Public Health.
7. Barat LM, Himonga B, Nkunika S et al. 1998. A systematic approach to the development of a rational malaria treatment policy in Zambia. Tropical Medicine and International Health 3: 535-42.
8. Baume C, Helitzer-Allen D, Kachur P. 2001. Patterns of care for childhood malaria in Zambia. Social Science and Medicine 51: 1491-503.
9. Bedregal P, Ferlie E. 2001. Evidence-based primary care? A multitier, multiple stakeholder perspective from Chile. International Journal of Health Planning and Management 16: 47-60.
10. nd edition). Thousand Oaks, CA: Sage Publications.
11. Bloland PB. 2003. A contrarian view of malaria therapy policy in Africa. American Journal of Tropical Medicine and Hygiene 68: 125-6.
12. Bloland PB, Ettling M. 1999. Making malaria-treatment policy in the face of drug resistance. Annals of Tropical Medicine and Parasitology 93: 5-23.
13. Bloland PB, Kazembe PN, Oloo AJ et al. 1998. Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa. Tropical Medicine and International Health 3: 543-52.
14. Bloland PB, Kachur SP, Williams HA. 2003. Trends in antimalarial drug deployment in sub-Saharan Africa. Journal of Experimental Biology 206: 3761-9.
15. Chima RI, Goodman C, Mills A. 2002. The economic impact of malaria in Africa: a critical review of the evidence. Health Policy 63: 17-36.
16. Durrheim DN, Sharp BL, Barnes K. 2001. Sentinel malaria surveillance: more than a research tool. South African Medical Journal 91: 968-70.
17. Durrheim DN, Speare R, Harries AD. 2002. Research that influences policy and practice - characteristics of operational research to improve malaria control in Mpumalanga Province, South Africa. Malaria Journal 1: 9-15.
18. Durrheim DN. Williams HA (in press). Assuring effective malaria treatment in Africa - drug efficacy is necessary but not sufficient. Invited 'Viewpoint' submission, Journal of Epidemiology and Community Health.
19. Durrheim DN, Williams HA, Barnes K, Speare R, Sharp B. 2003. Beyond evidence: a retrospective study of factors influencing a malaria treatment policy change in two South African provinces. Critical Public Health 13: 309-30.
20. Fevre EM, Barnish G. 1999. Review. Malaria treatment policies: when and how should they be changed? Annals of Tropical Medicine and Parasitology 93: 549-60.
21. Fogh S, Jepson S, Effersoe P. 1979. Chloroquine-resistant Plasmodium falciparum in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene 73: 228-9.
22. Foster S, Phillips M. 1998. Economics and its contribution to the fight against malaria. Annals of Tropical Medicine and Parasitology 92: 391-8.
23. Gilson L, Alilio M, Heggenhougen K. 1994. Community satisfaction with primary health care services: an evaluation undertaken in Morogoro region of Tanzania. Social Science and Medicine 39: 767-80.
24. Goodman C, Abdulla S, Coleman P et al. (in press).Choosing the first-line drug for malaria treatment - how can cost-effectiveness analysis inform policy? In: Roberts J (ed). Economics of infection.
25. Goodman CA, Coleman PG, Mills AJ. 1999. Cost-effectiveness of malaria control in sub-Saharan Africa. The Lancet 354: 378-85.
26. Goodman CA, Coleman PG, Mills AJ. 2001. Changing the first line drug for malaria treatment - cost-effectiveness analysis with highly uncertain inter-temporal trade-offs. Health Economics 10: 731-49.
27. Goodman C, Hanson K, Mills A. 2000. Understanding public and private sector interactions in the provision of malaria-related treatment. Paper presented at the International Conference on Health Systems Financing in Low-income African and Asian Countries, CERDI, Clermont, France, 30 November - 1 December.
28. Goodman CA, Mills AJ. 1999. The evidence base on the cost-effectiveness of malaria control measures in Africa. Health Policy and Planning 14: 301-12.
29. Guerin PJ, Olliaro P, Kosten F et al. 2002. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. The Lancet Infectious Diseases 2: 564-73.
30. Haak H. 2002. Access to antimalarial medicines: improving the affordability and financing of anemisinin-based combination therapies. Final report, December 2002. Geneva: Roll Back Malaria Department, Essential Drugs and Medicines Policy Department, World Health Organization.
31. Hall AJ. 2000. Mothers, malaria and resistance. Tropical Medicine and International Health 5: 753-54.
32. Hanney SR, Gonzalez-Block MA, Buxton MJ, Kogan M. 2003. The utilization of health research in policy-making: concepts, examples and methods of assessment. Health Research Policy and Systems 1: 2.
33. Hutubessy R, Chisholm D, Edejer TT and WHOCHOICE. 2003. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation 1: 8.
34. Innvær S, Vist G, Trommald M, Oxman A. 2002. Health policy-makers' perceptions of their use of evidence: a systematic review. Journal of Health Services Research and Policy 7: 239-44.
35. Jowett M, Miller N, Mnzava N. 2000. Malaria expenditure analysis. Tanzania case study. Report prepared for DFID-EA (Tanzania) and the Roll Back Malaria Initiative. York: International Programme, Centre for Health Economics, University of York.
36. Kachur SP, Abdulla S, Barnes K et al. 2001. Complex, and large, trials of pragmatic malaria interventions. Tropical Medicine and International Health 6: 324-25.
37. Kager PA. 2002. Malaria control: constraints and opportunities. Tropical Medicine and International Health 7: 1042-6.
38. Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG. 2002. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Tropical Medicine and International Health 7: 1031-41.
39. Kaul I, Faust M. 2001. Global public good and health: taking the agenda forward. Bulletin of the World Health Organization 79: 869-74.
40. Kindermans JM. 2002. Changing national malaria treatment protocols in Africa: what is the cost and who will pay? Case studies: Burundi, Kenya, Rwanda, Tanzania and Uganda. Unpublished paper for Access to Essential Medicines Campaign, Médecins Sans Frontières, version 1.
41. Kitua AY. 2000. Antimalarial drug policy: making systemic change. The Lancet 354: 32.
42. Kitua AY, Mashalla YJS, Shija JK. 2000. Coordinating health research to promote action: the Tanzanian experience. British Medical Journal 321: 821-3.
43. nd edition. West Hartford, CT: Kumarian Press, Inc.
44. McPake B, Asiimwe D, Mwesigye F et al. 1999. Informal economic activities of public health workers in Uganda: implications for quality and accessibility of care. Social Science and Medicine 49: 849-65.
45. Moerman F, Lengeler C, Chimumbwa J et al. 2003. The contribution of health-care services to a sound and sustainable malaria-control policy. The Lancet Infectious Diseases 3: 99-102.
46. Molyneux CS, Mung'ala-Odera V, Harpham T, Snow RW. 1999. Maternal responses to childhood fevers: a comparison of rural and urban residents in coastal Kenya. Tropical Medicine and International Health 4: 836-45.
47. rd Pan-African Conference on Malaria, Arusha, Tanzania, November.
48. Mutabingwa TK, Watkins WM, d'Alessandro U. 2002. Monitoring of drug-resistant malaria in Africa. The Lancet 360: 875.
49. Nosten F, Brasseur P. 2002. Combination therapy for malaria. The way forward? Drugs 62: 1315-29.
50. Oketch-Rabah RH, Oduol E, Oluka MA, Nyamwaya D. 1998. Use of traditional and pharmaceutical medicines in Kenya: the case of Kisumu and Rachuonyo Districts in Luo Nyanza. Paper presented at the Workshop on People and Medicines in East Africa, 16-20 November, 1998, Mbale, Uganda.
51. Reich MR. 1995. The politics of health sector reform in developing countries: three cases of pharmaceutical policy. Health Policy 32: 47-77.
52. Reynolds-Whyte S, Birungi H. 2000. The business of medicines and the politics of knowledge. In: LW Whiteford, L Manderson (eds). Global health policy, local realities. Boulder, CO: Lynne Rienner Publications, pp. 127-48.
53. Ringwald P, Sukwa T, Basco LK, Bloland P, Mendis K. 2002. Monitoring of drug-resistant malaria in Africa. The Lancet 360: 875-6.
54. Sauerborn R, Nitayarumphong S, Gerhardus A. 1999. Strategies to enhance the use of health systems research for health sector reform. Tropical Medicine and International Health 4: 827-35.
55. Shortell SM, Solomon MA. 1982. Improving health care policy research. Journal of Health Politics, Policy and Law 6: 684-702.
56. Shretta R, Omumbo J, Rapuoda B, Snow RW. 2000. Using evidence to change antimalarial drug policy in Kenya. Tropical Medicine and International Health 5: 775-764.
57. Steketee R, Macheso A, Heymann D et al. 1995. A decade of progress in malaria policy and program development in Malawî: 1984-1993. Atlanta: United States Agency For International Development and United States Department of Health and Human Services, Centers for Disease Control and Prevention.
58. The East African Network for Monitoring Antimalarial Treatment (EANMAT). 2001. Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience. Tropical Medicine and International Health 6: 891-8.
59. Trostle J, Bronfman B, Langer A. 1999. How do researchers influence decision-makers? Case studies of Mexican policies. Health Policy and Planning 14: 103-14.
60. Walt G. 1994. Health policy: an introduction to process and power. London: Zed Books Ltd.
61. Walt G, Gilson L. 1994. Reforming the health sector in developing countries: the central role of policy. Health Policy and Planning 9: 353-70.
62. Williams HA, Bloland PB. The process of decision-making as it relates to changing national malaria treatment policies. Unpublished manuscript.
63. Williams HA, Jones COH. 2004. A critical review of behavioral issues related to malaria control in sub-Saharan Africa: what contributions have social scientists made? Social Science and Medicine 59: 501-23.
64. Williams HA, Kachur PA, Nalwamba CN et al. 1997. A community perspective on the efficacy of malaria treatment options for children in Lundazi District, Zambia. Tropical Medicine and International Health 4: 641-52.
65. rd MIM Pan-African Conference on Malaria, Arusha, Tanzania, November.
66. Williams HA, Trupin C, Mwisongo A. 2001. A case study of the change in national malaria treatment guidelines in Tanzania: Preliminary findings. Paper presented at the annual meetings of the American Society for Tropical Hygiene and Medicine, Atlanta, GA, November.
67. Wongsrichanalai C, Thimasarn K, Sirichaisinthop J. 2000. Antimalarial drug combination policy: a caveat. The Lancet 355: 2245-6.
68. WHO. 1994. Antimalarial drug policies: data requirements, treatment of uncomplicated malaria and the management of malaria in pregnancy. WHO/MAL/94.1070. Geneva: World Health Organization.
69. WHO. 2001. Antimalarial drug combination therapy: report of a technical consultation. (Technical review: A Bosman, C Delacollette, P Olumese, A Rietveld and A Teklehaimanot). WHO/CDS/RBM/2001.Geneva: Roll Back Malaria Cabinet Project/World Health Organization.
70. WHO. 2002. The importance of pharmacogivilance: safety monitoring of medicinal products. Geneva: World Health Organization.
71. WHO. 2003. RBM Partnership Meeting on 'Improving Access to Antimalarial Medicines', 30 September-2 October, 2002. Draft report, World Health Organization, Geneva.
72. WHO/AFRO. 2000. Framework for developing, implementing and updating antimalarial treatment policy in Africa. A guide for country malaria control programmes. Final version, August. Harare: Malaria Programme, World Health Organization/African Regional Office.
73. Zuma ND. 1997. South Africa's new national drug policy. Journal of Public Health Policy 18: 98-105.